Neurosarcoidosis - an ever-present clinical challenge

Sarcoidosis afflicts the central nervous system more frequently than previously believed. Neurological symptoms are present in roughly one-half of patients, and depend on the location in the central nervous system. The probability of spontaneous regression is significantly less when compared to other forms of sarcoidosis, which means that the proper diagnosis and treatment is paramount. Even when properly treated, functional defects are not uncommon. Majority of these patients require immunomodulating drugs and continuous follow-up. New immunomodulating drugs, especially biological agents, have shown to be significantly more effective, with fewer side effects, and are important when corticosteroids could not be applied. Less invasive methods, such as cerebrospinal analysis, help greatly in the diagnostics procedure, and require further research and improvement.

[1]  Jacqueline A Palace,et al.  Effects of immunotherapies and clinical outcomes in neurosarcoidosis: a retrospective cohort study , 2021, Journal of Neurology.

[2]  R. Baughman,et al.  Biologic and advanced immunomodulating therapeutic options for sarcoidosis: a clinical update , 2021, Expert review of clinical pharmacology.

[3]  Liam D. Turner,et al.  A multi-center case series of sarcoid optic neuropathy , 2020, Journal of the Neurological Sciences.

[4]  Jonathan P. Giurintano,et al.  Neurosarcoidosis Directly Involving the Cervical Vagus Nerve , 2020, The Annals of otology, rhinology, and laryngology.

[5]  K. Salzman,et al.  Neurosarcoidosis , 2020, Neurology: Neuroimmunology & Neuroinflammation.

[6]  N. Unterwalder,et al.  Analysis of soluble interleukin-2 receptor as CSF biomarker for neurosarcoidosis , 2020, Neurology: Neuroimmunology & Neuroinflammation.

[7]  Z. Amoura,et al.  The cerebrospinal fluid CD4/CD8 ratio and interleukin‐6 and ‐10 levels in neurosarcoidosis: a multicenter, pragmatic, comparative study , 2019, European journal of neurology.

[8]  Bledi C. Brahimaj,et al.  Neurosarcoidosis Presenting as Isolated Bilateral Cerebellopontine Angle Tumors: Case Report and Review of the Literature , 2019, Ear, nose, & throat journal.

[9]  J. Vries,et al.  Everyday cognitive failure in patients suffering from neurosarcoidosis , 2019 .

[10]  V. Spasovski,et al.  Genes and metabolic pathway of sarcoidosis: identification of key players and risk modifiers , 2018, Archives of medical science : AMS.

[11]  Sun Ying,et al.  Neurosarcoidosis in a public safety net hospital: a study of 82 cases. , 2019, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[12]  M. Tezcan,et al.  Optic Neuropathy and Macular Ischemia Associated with Neurosarcoidosis: A Case Report , 2018, Turkish journal of ophthalmology.

[13]  V. Mihailović-Vučinić,et al.  Utility of angiotensin-converting enzyme activity in aqueous humor in the diagnosis of ocular sarcoidosis , 2017, Indian journal of ophthalmology.

[14]  E. Santos,et al.  Neurosarcoidosis according to Zajicek and Scolding criteria: 15 probable and definite cases, their treatment and outcomes , 2017, Journal of the Neurological Sciences.

[15]  D. Sobic-Saranovic,et al.  Verifying Sarcoidosis Activity: Chitotriosidase versus ACE in Sarcoidosis – a Case-control Study , 2016, Journal of medical biochemistry.

[16]  M. Mijajlovic,et al.  Diagnosis of neurosarcoidosis--necessity of biopsy. , 2014, Medicinski pregled.

[17]  M. Mijajlovic,et al.  Radiological presentation of neurosarcoidosis. , 2014, Medicinski pregled.

[18]  S. Simić-Ogrizović,et al.  Mystery called sarcoidosis: forty-four years follow-up of chronic systemic disease. , 2012, Srpski arhiv za celokupno lekarstvo.